Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma

NCT06023875 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Locally Advanced Operable

Interventions

DRUG: Cadonilimab
DRUG: Docetaxel
DRUG: Cisplatin

Sponsor

Xuekui Liu